1. ASCO. Outcomes of cancer treatment for technology assessment and cancer treatment guidelines // J. Clin. Oncol. 1996. 14. (3). 671–679.
2. US Food and Drug Administration: Guidance for Industry. Patient-reported outcome measures: use in medical product development to support labeling claims. Available from webcite U.S. FDA, Clinical/Medical; 2009.
3. Новик А.А., Ионова Т.И. Руководство по исследованию качества жизни в медицине (3-е изд., перераб. и доп.) / Ред. Ю.Л. Шевченко. М.: РАЕН, 2012. 528 с.
4. Gorodokin G., Novik A. Quality of cancer care // Ann. Oncol. 2005. 16. (6). 991.
5. Moskowitz C.H. An update on the management of relapsed and refractory Hodgkin’s Lymphoma // Semin. Oncol. 2004. 31. 54–59.
6. Moskowitz C.H. Outcome of patients with primary refractory HD treated with high dose combined modality therapy and ASCT // Br. J. Haematol. 2004. 124. 645–652.
7. Tannock I.F. Treating the patient, not just the cancer // N. Engl. J. Med. 1987. 317. 1534–1535.
8. Ионова Т.И., Рыков И.В., Калядина С.А. Популяция больных гемобластозами гетерогенна по интегральному показателю качества жизни // Вестн. Межнац. центра исследования качества жизни. 2007. (9–10). 99–108.
9. Bertero C., Eriksson B.E., Ek A.C. Explaining different profiles in quality of life experiences in acute and chronic leukemia // Cancer Nurs. 1997. 20. (2). 100–104.
10. Coates A.S., Porzsolt F., Osoba D. Quality of life in oncology practice: prognostic value of EORTC QLQ–C30 scores in patients with advanced malignancy // Eur. J. Cancer. 1997. 33. 1025–1030.
11. Dancey J., Zee B., Osoba D. Quality of life scores: an independent prognostic variable in a general population of cancer patients receiving chemotherapy // Can. Med. Assoc. J. 1996. 10. 225–230.
12. Gulbrandsen N., Hjermstad M.J., Wisloff F. Interpretation of quality of life scores in multiple myeloma by comparison with a reference population and assessment of the clinical importance of score differences // Eur. J. Haematol. 2004. 72. (3). 172.
13. Wisloff F., Hellstrom-Lindberg E., Lindberg G. et al. A validated decision model for treating the anemia of myelodysplastic syndromes with erythropoietin and G–CSF – significant effects on quality of life // Br. J. Haematol. 2003. 120. 1037–1046.
14. Hwang S.S., Scott C.B., Chang V.T. et al. Prediction of survival for advanced cancer patients by recursive partitioning analysis: role of Karnofsky performance status, quality of life, and symptom distress // Cancer Invest. 2004. 22. 678–687.
15. Jerkeman M., Kaasa S., Hjermstad M. et al. Health–related quality of life and its potential prognostic implications in patients with aggressive lymphoma: a Nordic Lymphoma Group Trial // Med. Oncol. 2001. 18. (1). 85–94.
16. Novik A.A., Ionova T.I., Povzun A.S. et al. Quality of life of in patients with different types of leukemia // Qual. Life Res. 2000. 9. (3). 294.
17. Novik A., Ionova T., Kishtovich A. Heterogeneity of new lymphoma patients in terms of quality of life parameters // Blood. 2003. 22. 302.
18. Sedman A.D., Porteney R., Yao T.J. et al. Quality of life in Phase II Trials: a study of methodology and predictive value in patients with advance breast cancer treated with Paclitaxel plus granulocyte colony stimulating factor // J. Nat. Cancer Inst. 1995. 87. 1316–1322.
19. Guidelines. Patient-reported outcomes in hematology. Eds. A. Novik, S. Salek, T. Ionova. Genoa: Forum service editore, 2012.
20. Ионова Т.И. Концептуальные и методологические аспекты исследования качества жизни в онкогематологии: автореф. дис. … докт. биол. наук. СПб., 2009.